ESLA Stock Analysis: Buy, Sell, or Hold?
ESLA - Estrella Immunopharma, Inc. Common Stock
$1.00
0.07 (7.05%)
▲
5d:
-2.91%
30d:
-11.5%
90d:
-1.96%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ESLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ESLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ESLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ESLA is currently trading at $1.00, which is considered oversold relative to its 30-day fair value range of $1.02 to $1.15.
Technical Outlook: Technically, ESLA is in a uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ESLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+1100.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ESLA is in a uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: ESLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+1100.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.02 -
$1.15
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 1100.0% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$1.02 -
$1.15
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.02
Resistance Level
$1.24
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.12
Wall Street Target
$12.00
(+1100.0%)
Share & Embed Analysis
Last updated: June 24, 2026 1:05 AM ET
Data refreshes hourly during market hours. Next update: 2:05 AM
Data refreshes hourly during market hours. Next update: 2:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
